JP Morgan Chase’s DICE Therapeutics DICE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
– Sell
-126,300
Closed -$5.87M – 7859
2023
Q2
$5.87M Buy
+126,300
New +$4.37M ﹤0.01% 2736
2022
Q4
– Sell
-58,200
Closed -$1.18M – 7205
2022
Q3
$1.18M Buy
58,200
+23,200
+66% +$423K ﹤0.01% 3877
2022
Q2
$543K Buy
+35,000
New +$602K ﹤0.01% 4504

JP Morgan Chase's DICE Position: Q3 2023 in Review

JP Morgan Chase sold out of DICE Therapeutics (DICE) in Q3 2023, closing a stake of 618,089 shares — an estimated $28.7M sold.

JP Morgan Chase first reported a position in DICE in Q4 2021 and held it in 7 quarters. The position peaked at $28.7M in Q2 2023. 0 funds tracked by Wall St. Rank hold DICE as of Q3 2023.

  • JP Morgan Chase reported no remaining DICE Therapeutics position as of Q3 2023 after selling out during the quarter.
  • JP Morgan Chase sold 618,089 DICE Therapeutics shares in Q3 2023, an estimated $28.7M.
  • JP Morgan Chase first reported a position in DICE Therapeutics in Q4 2021 and held it in 7 quarters.
  • JP Morgan Chase's DICE Therapeutics position peaked at $28.7M in Q2 2023.
  • 0 funds tracked by Wall St. Rank held DICE Therapeutics as of Q3 2023.

Based on JP Morgan Chase's 13F filing for Q3 2023, filed 14 Nov 2023.